← All trials
NCT05359211
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 28, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- May 3, 2022
- Last posted
- Nov 29, 2022
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- Nektar TherapeuticsCollaborator
- University of WashingtonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.